Seeking Alpha

Hanki

Hanki
Send Message
View as an RSS Feed
View Hanki's Comments BY TICKER:
Latest  |  Highest rated
  • Advanced Cell Technology: A Key Patent Critique [View article]
    JMY sell all your BTX and just maybe you will get some of your credibility back. Some good advise stay out of the gene expression science...... Matt calls 'em how he see 'em.
    Apr 9, 2014. 12:43 PM | 6 Likes Like |Link to Comment
  • Advanced Cell Technology On The Doorstep [View article]
    Please do self analysis on the eMSC paper and you will find several gems in the paper regarding why embryonic stem cells are the gold standard. The difference of cell surface marker and gene expression shown in the paper related to data shows why eMSC are more potent vs. adult stem cells that lack certain cell markers.

    There will be no comparison of adult like cell vs. embryonic RPE because of ACTC lead in the field and strategy of replacement of epithelium. Why compare the gold standard when ACTc is so far ahead? The one company to give ACTC a run for their money in the AMD is Mike West's Biotime because of their ownership of blastocysts patent(s) that gives biotime away to embryonic cell lines.
    Apr 8, 2014. 03:27 AM | 1 Like Like |Link to Comment
  • New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties [View article]
    It is about time...... so if you are using adult stem cells in your companies and research are you going to use embryonic MSC as a positive control in your flow data and gene expression data?
    Mar 24, 2014. 05:28 PM | 2 Likes Like |Link to Comment
  • Advanced Cell Technology's Intellectual Property Takes A Hit [View article]
    When is there going to be a retraction here at SA, when the Nature article is retracted as being reported by one of the co-authors?
    Mar 10, 2014. 03:23 PM | 1 Like Like |Link to Comment
  • Advanced Cell Technology: Took A Hit Or Preparing To Throw A Knockout Blow? [View article]
    Another good site is "google The ACT Discussion Forum" some good people there, too. They are mostly traders, with some longs

    http://bit.ly/1f7yrgR
    Mar 7, 2014. 01:51 PM | Likes Like |Link to Comment
  • StemCells, Inc. And Advanced Cell Technology: The Race To Treat AMD [View article]
    But Different gene expression

    Let’s try this argument, a biologics comparisons from neural stem cells with RPE stem cells. The neural stem cells, that Stem Inc., have are the major neuroimmune interactions being IL-2, IL-6, IFN-gamma and TNF-alpha. So, scientific fact is these proteins are different cytokines than RPE cells output in gene expression. The only common cytokine is TNF-alpha with RPE cells. In fact neural cytokines are based upon the anatomically distinct cells releasing protein specific of the synaptic microenvironments in the nervous system or eye physiology dynamic status.

    What is the main function of TNF-alpha? It is as a critical mediator of chronic neuro-inflammation-ind... neuronal dysfunction and apoptosis? So you see these two stem cell lineage are program differently and have specifically different functions in the immune system.

    Therefore why not replace dead RPE cells with young embryonic RPE cells. Lanza’s ACTc strategy is pure and simple of single cell suspension.
    Mar 6, 2014. 10:48 PM | Likes Like |Link to Comment
  • StemCells, Inc. And Advanced Cell Technology: The Race To Treat AMD [View article]
    In the normal retina, the RPE performs the functions of barrier, macrophage,and neuroprotective cell layer. During aging and in the presence of disease the robustness of each of these functions diminishes. Transplantation of ACTC’s
    hESC Derived RPE (MA09-hRPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (Dry AMD) is all about attachment to vascularity structures with cell surface receptors. We know that we have a reboot, rescue and repair in the eye going on. We know ACTC has the data we all have seen the embedded layers of RPE cells from ACTC power points slides.

    Let’s talk science of homeostasis in AMD/SMD retinal macrophages since it have been shown to produce IL-8, IL-1 beta, MCP monocytes chemotatic protein along with TNF-alpha in the inflammatory cascade in AMD /SMD . This micro environment that is dynamic and controlled by matrix metallo proteinases (MMPs) and tissue inhibitors of MMPs (TIMPs) which may evoke or augment mononuclear phagocyte-mediated ocular inflammation by RPE . RPE plays an important role in the up regulation of expression of MMP-1, 2,and -3 and account for a directional shift in the balance between MMPs and TIMPs

    Can the same be said of Stems’s neural cells? I would argue no, the DNA is different, it is that simple. This is why one injects 1 million neural cells to mask the functions because the neural cells are out of place in the functions and possible repair of dead epithelium. Just replace the dead with new 100k of ACTc RPE’s and call it a day.
    Mar 6, 2014. 10:46 PM | 1 Like Like |Link to Comment
  • StemCells, Inc. And Advanced Cell Technology: The Race To Treat AMD [View article]
    IMO the hidden pony is the eMSC dog trials at Tufts Vet school for auto immunity and infections that ACTc is doing now with human embryonic cells . Pre-IND for Lupus. Lanza has the data. I would not touch STEM with aborted fetus tissue as my starting point. Talk about hell . Embryonic NED cell lines is the way to go. It is natures truth and Potency is the most important cellular fact. I would argue that STEM is trying to keep up with the Jones. They are cutting corners all over, less data points, little animal trials Etc. What happens to the race when TLD 33 data points are publish in peer review journal the near future and move to Phase IIb/III this spring? Byers be ware of STEM.
    Mar 5, 2014. 01:18 PM | 7 Likes Like |Link to Comment
  • Advanced Cell Technology: A Balanced Perspective Of Risk And Reward [View article]
    What is going on in London today re ACTC?
    Mar 5, 2014. 04:03 AM | Likes Like |Link to Comment
  • Advanced Cell Technology: Took A Hit Or Preparing To Throw A Knockout Blow? [View article]
    you guys need to look at investorstemcell.com if you are serious about ACTC
    Mar 5, 2014. 03:45 AM | Likes Like |Link to Comment
  • Advanced Cell Technology: Took A Hit Or Preparing To Throw A Knockout Blow? [View article]
    a 1:30 to 1:100 RS was approved by the shareholders in October 2013 ASM to be done by September 30, 2014.
    Feb 19, 2014. 06:14 PM | 2 Likes Like |Link to Comment
  • Advanced Cell Technology: Took A Hit Or Preparing To Throw A Knockout Blow? [View article]
    Nice summary of things in the pipeline. DD on Tufts Vet with MSC is a must if you think the RPE is big. ACTC has put lupus in the IND timeline, therefore Lanza must have pre-IND data for filing. Very nice comparison of Regeneron wet market.
    Feb 19, 2014. 06:02 PM | Likes Like |Link to Comment
  • Advanced Cell Technology: Took A Hit Or Preparing To Throw A Knockout Blow? [View article]
    Focus on AMD/ SMD diseases, there are 33 patients that will not trade these embryonic RPE cells for drug trials. Ask the cowboy who has 20/40 acuity improvement fro 20/400 after a month, what he thinks about cellular therapy???I agree 100% with your written analyses. Thanks
    Feb 19, 2014. 05:56 PM | 2 Likes Like |Link to Comment
  • Advanced Cell Technology's Intellectual Property Takes A Hit [View article]
    I think you need to do some homework on eMSC and 10 dog trials at Tufts Vet with human embryonic cells. It is clear to me you do not understand a thing about product development and manufacturing of a medical product what is need in RPE manufacturing? And here is why...... how many Platelets are in unit? and how many cells are needed for this process? So the Platelets project is 7-10 year away with automation. I know because I have been working on this problem for 8 years....
    AMD/ SMD dose is 100K of RPE at present. When do you think there are getting BT? 2014-15? So you are blowing smoke with statements about IP for iPSC........
    As far as an expert opinion . Have they every put out a stem cell product? Say a CD34+ monoclonal antibodies for example.
    Feb 12, 2014. 01:22 PM | 4 Likes Like |Link to Comment
  • Advanced Cell Technology's Intellectual Property Takes A Hit [View article]
    I would argue that Advanced Cell Technology has been building a patent portfolio around a major embryonic (hESC) cells strategy and not iPSC as you assert. Platelets are a minor strategy compared with RPE and eMSC projects. This iPSC is one of three large projects that could also use hESC. And I would argue #3 behind the other two major projects that any Biotech or big Pharma will pay dearly to own ACTC’s IP.

    The new finding from acid induce methodology in Nature article will not eradicate any future value of ACT's embryonic patents. Your other points are with biases and speculations that the process for inducing pluripotency is most likely applicable to from the Nature article with human stem cells is not a fact in vivo nor in vitro. So, we will see.


    Furthermore, the company had announced very interesting plans to use their hESC technology to make eMSC in ten dog trials that leads to INDs and several JVs. While such a plan would still be possible, the new findings indicate that ACT's IP would be the most efficient means to this end in manufacturing allogeneic stem cell treatment and manufacturing vs. a costly limited autologous methodology.


    Although this does not affect the outcome of Advanced Cell Technology's ongoing trials, but you do not explain how it will affect the cost of commercialization and thus will not certainly impacts the company's future plans and value.


    Therefore your article is misleading and misrepresentative of ACTC near future plans. The RPE cells derived from embryonic stem cells, which are still the "gold standard" rather than induced ones. Early success reports some patients with acuity improvement and the fact that there currently are no available treatments.


    I will tell you here at SA that Lanza cell banks for many reasons are the bottom line in COG to manufacture a reliable, reproducible, allogeneic and stable medical product. So the argument is what are the best cells to use for effective cellular therapy? What works the best?
    Feb 12, 2014. 11:46 AM | 10 Likes Like |Link to Comment
COMMENTS STATS
28 Comments
54 Likes